The processing and timing of key cell cycle events can become dysregulated, leading to CIN through abnormal PLK1 activities, and in this review, we discuss therapeutic avenues that may arise from near-ubiquitous PLK1 deregulation in cancer cells. The gene discussed is PLK1; the disease is cancer.